Nemaura includes insulin on list of drugs eligible for EU DuoPack license

Nemaura Medical announced that it now includes insulin on the list of drugs under the DuoPack Commercial License Agreement with its licensee, MySugarWatch DuoPack Limited, MSWDL. The two companies have now agreed to include injectable insulin for the European market as part of this agreement, as patent expiry allows, in addition to the originally agreed upon medicines. It is estimated that as many as 4 million older patients of the approximately 20 million patients in the combined territories of UK and the EU with Type 2 diabetes receive insulin. "The inclusion of insulin in our agreement with MSWDL means patients with Type 2 diabetes will have access to a CGM-guided insulin dose titration care model that is designed to reduce hypoglycemic episodes and hospital admissions while improving long-term outcomes," commented Nemaura CEO Dr. Faz Chowdhury. "Moreover, it uniquely avoids a potentially bruised, slow to heal, infection prone, needle induced skin puncture wound in older patients at the site of a CGM sensor skin application. We are eager to provide potential improvements in monitoring and lifestyle for the millions of Type 2 diabetes patients globally."